“Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated With a Novel Combination Treatment With Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab)”. Archives of Clinical and Medical Case Reports 4, no. 1 (January 2, 2020): 8–14. Accessed September 11, 2026. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22266.